26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.
November 2025 in “Frontiers in Immunology” This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.
63 citations
,
March 2020 in “Clinical Cosmetic and Investigational Dermatology” This study suggests that the prevalence of alopecia areata in the US remains similar to high estimates from the 1970s, with significant implications for quality of life.
October 2023 in “International journal of rheumatic diseases” This study found that the JAK3/TEC kinase inhibitor ritlecitinib was effective and well tolerated in patients aged 12 and older with alopecia areata, providing a potential systemic treatment option for this condition, especially in cases of significant psychosocial impact.
This congress summary highlights the COMEF 2023 event, which focused on medical ethics, education, and health through discussions with the theme "Learn, practice, excel," but reports no new research findings.